6. パーキンソン病 Parkinson disease Clinical trials / Disease details
臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1900025894 | 2019-09-11 | 2019-09-12 | Parallel randomized controlled trial for Shengyang Yiwei Granule in the treatment of early Parkinson's disease | Parallel randomized controlled trial for Shengyang Yiwei Granule in the treatment of early Parkinson's disease | parkinson disease | experimental group:Parkinson's disease routine medication, plus Shengyang Yiwei granules, water blunt, one dose, morning and evening;control group:Parkinson's disease routine medication, add Buzhong Yiqi granules, water blunt, one dose, morning and evening; | Kaida Wang | NULL | Recruiting | Both | experimental group:45;control group:23; | China | |||
| 2 | ITMCTR1900002593 | 2019-09-11 | 2019-09-12 | Parallel randomized controlled trial for Shengyang Yiwei Granule in the treatment of early Parkinson's disease | Parallel randomized controlled trial for Shengyang Yiwei Granule in the treatment of early Parkinson's disease | parkinson disease | experimental group:Parkinson's disease routine medication, plus Shengyang Yiwei granules, water blunt, one dose, morning and evening;control group:Parkinson's disease routine medication, add Buzhong Yiqi granules, water blunt, one dose, morning and evening; | Kaida Wang | NULL | Recruiting | Both | experimental group:45;control group:23; | China | |||
| 3 | JPRN-UMIN000019654 | 2015/11/06 | 06/11/2015 | The effect of rich-hydrogen water drinking to gut peptide | The effect of rich-hydrogen water drinking to gut peptide - The effect of rich-hydrogen water drinking to gut peptide | Parkinson's disease, healthy control | hydrogen water natural water | Nagoya graduate school of medicine university | NULL | Pending | 20years-old | 80years-old | Male and Female | 40 | Not applicable | Japan |
| 4 | JPRN-UMIN000019090 | 2015/11/04 | 01/11/2015 | Reduced form of CoenzymeQ10 for Parkinson's disease - open trial of dose finding test and combination with hydrogen water | Reduced form of CoenzymeQ10 for Parkinson's disease - open trial of dose finding test and combination with hydrogen water - Dose finding test of reduced form of Coenzyme Q10 for Parkinson's disease | Parkinson's disease | reduced form of CoQ10 300mg 16weeks reduced form of CoQ10 600mg 16weeks reduced form of CoQ10 600mg 16weeks hydrogen water 500ml(Suisosui 7.0) 16weeks | Juntendo University Koshigaya Hospital | NULL | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 45 | Not selected | Japan |
| 5 | JPRN-UMIN000010014 | 2013/02/28 | 13/02/2013 | Randomized Double-blind, Placebo-controlled multi-center trial on molecular hydrogen water in Parkinson Disease | Randomized Double-blind, Placebo-controlled multi-center trial on molecular hydrogen water in Parkinson Disease - Randomized Double-blind, Placebo-controlled trial on hydrogen water in Parkinson Disease | Parkinson's disesase | hydrogen water made by "Suisosui5.0" placebo-water (nitrogen filling water) | Juntendo University School of Medicine, Neurology | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 200 | Not selected | Japan |
| 6 | JPRN-UMIN000007497 | 2010/01/01 | 14/03/2012 | Trial of molecular hydrogen water in Parkinson disease | Trial of molecular hydrogen water in Parkinson disease - Randomized Double-blind, Placebo-controlled trial on molecular hydrogen water in Parkinson Disease | Parkinson disease | The subjects should make 1000 ml of molecular hydrogen water which contains 1.6 ppm dissolved hydrogen by Aquerable, and consume for 48 weeks. Placebo water which is not contained molecular hydrogen water made from pseudo-machine. The subjects consume for48 weeks. | Department of Neurology, Juntendo University School of Medicine | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 18 | Not applicable | Japan |
| 7 | NCT00024622 (ClinicalTrials.gov) | March 15, 2002 | 23/9/2001 | PET Scanning in Parkinson s Disease | Positron Emission Tomography (PET) Scanning in Dopamine Disorders: Parkinson's Disease and Schizophrenia | Schizophrenia;Parkinson's Disease | Drug: 18F-Fluoro-L-dopa;Drug: O-15 Water | National Institute of Mental Health (NIMH) | NULL | Recruiting | 18 Years | 90 Years | All | 580 | United States | |
| 8 | NCT00001258 (ClinicalTrials.gov) | November 26, 1993 | 3/11/1999 | Studies of Frontal Lobe Brain Functioning in Schizophrenia | Studies of Frontal Lobe Function During Cognitive Stimulation as Measured With Oxygen-15 Water Positron Emission Tomography in Normal Subjects and Patients With Neuropsychiatric Disorders | Healthy Subjects;Schizophrenia;Parkinson Disease | Drug: Oxygen-15 Water | National Institute of Mental Health (NIMH) | NULL | Completed | 18 Years | 90 Years | All | 1039 | United States |